File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

TitleOutcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity
Authors
KeywordsCOPD
COPD control
COPD exacerbation
COVID-19
Issue Date16-Jun-2024
PublisherSpringer Nature
Citation
Scientific Reports, 2024, v. 14, n. 1 How to Cite?
Abstract

While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences of COVID-19 infection on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted in Hong Kong to investigate the persistent and delayed outcomes of patients with COPD who had COVID-19 infection of different severity (mild-moderate COVID-19 and severe COVID-19), compared with those who did not. Chinese patients with COPD ≥ 40 years old were recruited from March to September 2021. They were prospectively followed up for 24.9 ± 5.0 months until 31st August 2023. The primary outcome was the deterioration in COPD control defined as the change in mMRC dyspnea scale. The secondary outcomes included the change in exacerbation frequency and non-COVID-19 respiratory mortality (including death from COPD exacerbation or bacterial pneumonia). 328 patients were included in the analysis. Patients with mild-moderate and severe COVID-19 infection had statistically significant increased risks of worsening of mMRC dyspnoea scale by increase in 1 score from baseline to follow-up with adjusted odds ratios of 4.44 (95% CI = 1.95–10.15, p < 0.001) and 6.77 (95% CI = 2.08–22.00, p = 0.001) respectively. Patients with severe COVID-19 infection had significantly increased risks of increase in severe COPD exacerbation frequency with adjusted odds ratios of 4.73 (95% CI = 1.55–14.41, p = 0.006) non-COVID-19 respiratory mortality from COPD exacerbation or pneumonia with adjusted hazard ratio of 11.25 (95% CI = 2.98–42.45, p < 0.001). After recovery from COVID-19, worsening of COPD control from worsening of dyspnea, increase in severe exacerbation frequency to non-COVID-19 respiratory mortality (COPD exacerbation and pneumonia) was observed among patients with severe COVID-19. Mild to moderate COVID-19 was also associated with symptomatic deterioration.


Persistent Identifierhttp://hdl.handle.net/10722/347249
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 0.900

 

DC FieldValueLanguage
dc.contributor.authorKwok, Wang Chun-
dc.contributor.authorChau, Chi Hung-
dc.contributor.authorTam, Terence Chi Chun-
dc.contributor.authorLam, Fai Man-
dc.contributor.authorHo, James Chung Man-
dc.date.accessioned2024-09-20T00:30:56Z-
dc.date.available2024-09-20T00:30:56Z-
dc.date.issued2024-06-16-
dc.identifier.citationScientific Reports, 2024, v. 14, n. 1-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/10722/347249-
dc.description.abstract<p>While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences of COVID-19 infection on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted in Hong Kong to investigate the persistent and delayed outcomes of patients with COPD who had COVID-19 infection of different severity (mild-moderate COVID-19 and severe COVID-19), compared with those who did not. Chinese patients with COPD ≥ 40 years old were recruited from March to September 2021. They were prospectively followed up for 24.9 ± 5.0 months until 31st August 2023. The primary outcome was the deterioration in COPD control defined as the change in mMRC dyspnea scale. The secondary outcomes included the change in exacerbation frequency and non-COVID-19 respiratory mortality (including death from COPD exacerbation or bacterial pneumonia). 328 patients were included in the analysis. Patients with mild-moderate and severe COVID-19 infection had statistically significant increased risks of worsening of mMRC dyspnoea scale by increase in 1 score from baseline to follow-up with adjusted odds ratios of 4.44 (95% CI = 1.95–10.15, p < 0.001) and 6.77 (95% CI = 2.08–22.00, p = 0.001) respectively. Patients with severe COVID-19 infection had significantly increased risks of increase in severe COPD exacerbation frequency with adjusted odds ratios of 4.73 (95% CI = 1.55–14.41, p = 0.006) non-COVID-19 respiratory mortality from COPD exacerbation or pneumonia with adjusted hazard ratio of 11.25 (95% CI = 2.98–42.45, p < 0.001). After recovery from COVID-19, worsening of COPD control from worsening of dyspnea, increase in severe exacerbation frequency to non-COVID-19 respiratory mortality (COPD exacerbation and pneumonia) was observed among patients with severe COVID-19. Mild to moderate COVID-19 was also associated with symptomatic deterioration.</p>-
dc.languageeng-
dc.publisherSpringer Nature-
dc.relation.ispartofScientific Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOPD-
dc.subjectCOPD control-
dc.subjectCOPD exacerbation-
dc.subjectCOVID-19-
dc.titleOutcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41598-024-64670-9-
dc.identifier.pmid38880813-
dc.identifier.scopuseid_2-s2.0-85196058068-
dc.identifier.volume14-
dc.identifier.issue1-
dc.identifier.eissn2045-2322-
dc.identifier.issnl2045-2322-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats